Letrox (Levothyroxine Sodium, Hydrate)

Levothyroxine is a synthetic form of thyroxine (T4). After oral absorption, it is converted in peripheral tissues to the active hormone triiodothyronine (T3). T3 binds nuclear thyroid receptors, influencing gene expression that regulates basal metabolic rate, protein synthesis, and growth, thereby compensating for deficient thyroid function.

The dose of Letrox is individualized. A prescribing clinician determines the appropriate amount based on the patient’s age, weight, severity of thyroid deficiency, and laboratory results such as TSH and free T4 levels. Patients should follow the prescriber’s instructions and have regular monitoring.

The safety category for Letrox in pregnancy and lactation is not specified in the available data. Thyroid hormone replacement is often required during pregnancy, but any decision should be made by a qualified healthcare professional who can weigh potential benefits and risks for both mother and child.

To order Letrox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Letrox is a levothyroxine sodium formulation, comparable to other synthetic T4 products such as Synthroid or Euthyrox. All provide the same active hormone, but differences may exist in excipients, bioavailability, and regulatory approvals. Clinicians choose a product based on patient tolerance, cost, and local availability.

Letrox tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and avoid storing in humid areas such as bathrooms.

Letrox is taken orally, usually once daily on an empty stomach, preferably 30‑60 minutes before breakfast. The tablet should be swallowed whole with a full glass of water. Patients should not crush or chew the tablet unless instructed otherwise by a healthcare professional.

Serious risks include cardiac arrhythmias, angina or myocardial infarction, severe bone loss leading to osteoporosis, and allergic reactions such as rash, swelling or anaphylaxis. Patients with pre‑existing heart disease or bone disorders should be monitored closely while on therapy.

Letrox is contraindicated in patients with untreated adrenal insufficiency, acute myocardial infarction, or known hypersensitivity to levothyroxine or any tablet excipients. It should also be used with caution in individuals with severe cardiovascular disease, uncontrolled hypertension, or those taking interacting medications without medical supervision.